RT Journal Article
SR Electronic
T1 Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.10.20246751
DO 10.1101/2020.12.10.20246751
A1 Alana L. Whitcombe
A1 Reuben McGregor
A1 Alyson Craigie
A1 Alex James
A1 Richard Charlewood
A1 Natalie Lorenz
A1 James M.J. Dickson
A1 Campbell R. Sheen
A1 Barbara Koch
A1 Shivani Fox-Lewis
A1 Gary McAuliffe
A1 Sally A. Roberts
A1 Susan C. Morpeth
A1 Susan Taylor
A1 Rachel H. Webb
A1 Susan Jack
A1 Arlo Upton
A1 James Ussher
A1 Nicole J. Moreland
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.12.10.20246751.abstract
AB Objectives Circulating antibodies are important markers of previous infection and immunity. Questions remain with respect to the durability and functionality of SARS-CoV-2 antibodies. This study explored antibody responses in recovered COVID-19 patients in a setting where the probability of re-exposure is effectively nil, owing to New Zealand’s successful elimination strategy.Methods A triplex bead-based assay that detects antibody isotype (IgG, IgM and IgA) and subclass (IgG1, IgG2, IgG3, IgG4) responses against Nucleocapsid (N) protein, Receptor Binding Domain (RBD) and Spike (S) protein of SARS-CoV-2 was developed. After establishing baseline levels with pre-pandemic control sera (n=113), samples from PCR-confirmed COVID-19 patients with mild-moderate disease (n=189) collected up to eight months post-infection were examined. The relationship between antigen-specific antibodies and neutralising antibodies (NAbs) was explored with a surrogate neutralisation assay that quantifies inhibition of the RBD/hACE-2 interaction.Results While most individuals had broad isotype and subclass responses to each antigen shortly after infection, only RBD and S protein IgG, as well as NAbs, were stable over the study period, with 99%, 96% and 90% of samples, respectively, having responses over baseline 4-8 months post-infection. Anti-RBD antibodies were strongly correlated with NAbs at all time points (Pearson’s r ≥ 0.87) and feasibility of using finger prick sampling to accurately measure anti-RBD IgG was demonstrated.Conclusion Antibodies to SARS-CoV-2 persist for up to eight months following mild to moderate infection. This robust response can be attributed to the initial exposure without immune boosting given the lack of community transmission in our setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the School of Medicine Foundation (University of Auckland) and the COVID-19 Innovation Acceleration Fund (Ministry of Business, Innovation and Employment).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Health and Disability Ethics Committees New ZealandAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, NM, upon reasonable request.